Schectman G, Kaul S, Cherayil G D, Lee M, Kissebah A
Medical College of Wisconsin, Milwaukee.
Ann Intern Med. 1989 Mar 1;110(5):346-52. doi: 10.7326/0003-4819-110-5-346.
To determine whether high doses of fish oil concentrate followed by low-dose maintenance therapy can sustain the initial plasma triglyceride reductions.
Before-and-after trial with 3-month treatment periods.
Outpatient lipid clinic at a university medical center.
Sixteen patients with hypertriglyceridemia recruited from the General Internal Medicine Clinics. Five had concomitant hypercholesterolemia (type IIb).
Fish oil supplementation at two doses. After basal measurements, 9.8 g/d omega-3 fatty acids were provided for study months 1 to 3, and 3.9 g/d were provided for study months 4 to 6.
Blood was drawn monthly and plasma was analyzed for levels of triglycerides, low-density-lipoprotein (LDL) cholesterol and apolipoprotein B, high-density-lipoprotein (HDL) cholesterol and apolipoprotein A1, and glucose and glycohemoglobin. During therapy with the higher dose, mean plasma triglyceride levels were reduced from 3.65 +/- 0.35 mmol/L at baseline to 1.85 +/- 0.20 mmol/L at 1 month, but increased by 30% to 2.40 +/- 0.30 mmol/L by the third month of therapy (P less than 0.05): this increase could not be explained by changes in body weight or compliance. Plasma triglyceride levels continued to increase with low-dose therapy and remained only 11% below baseline values by the sixth month of therapy (P = not significant). Although fish oil therapy increased HDL cholesterol levels (+18% at high dose; 99% CI, 5% to 31%), favorable changes were not seen in LDL cholesterol, apolipoprotein B, or apolipoprotein A1 levels.
Fish oil concentrate at high doses followed by low-dose maintenance therapy cannot sustain the initial large plasma triglyceride reductions. Moreover, the efficacy of the higher dose becomes less pronounced after the first month of therapy. This reduced efficacy during prolonged therapy, and the lack of beneficial effect on apolipoprotein and LDL cholesterol levels, may limit the practical benefit of fish oil in the treatment of hypertriglyceridemia.
确定高剂量鱼油浓缩物继以低剂量维持治疗是否能维持最初的血浆甘油三酯降低水平。
为期3个月治疗期的前后对照试验。
大学医学中心的门诊脂质诊所。
从普通内科诊所招募的16例高甘油三酯血症患者。5例伴有高胆固醇血症(IIb型)。
两种剂量的鱼油补充剂。在进行基础测量后,第1至3个月给予9.8克/天的ω-3脂肪酸,第4至6个月给予3.9克/天。
每月采血,分析血浆中的甘油三酯、低密度脂蛋白(LDL)胆固醇和载脂蛋白B、高密度脂蛋白(HDL)胆固醇和载脂蛋白A1、葡萄糖和糖化血红蛋白水平。在高剂量治疗期间,平均血浆甘油三酯水平从基线时的3.65±0.35毫摩尔/升降至第1个月时的1.85±0.20毫摩尔/升,但在治疗的第3个月时升高了30%,达到2.40±0.30毫摩尔/升(P<0.05):这种升高无法用体重变化或依从性来解释。低剂量治疗期间血浆甘油三酯水平持续升高,到治疗第6个月时仅比基线值低11%(P=无显著性差异)。尽管鱼油治疗使HDL胆固醇水平升高(高剂量时升高18%;99%可信区间,5%至31%),但LDL胆固醇、载脂蛋白B或载脂蛋白A1水平未见有利变化。
高剂量鱼油浓缩物继以低剂量维持治疗不能维持最初显著的血浆甘油三酯降低水平。此外,高剂量治疗的疗效在治疗第1个月后变得不那么明显。长期治疗期间疗效降低,且对载脂蛋白和LDL胆固醇水平缺乏有益作用,可能会限制鱼油在治疗高甘油三酯血症中的实际益处。